A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

Roche’s Columvi (glofitamab) has been approved by the European Commission (EC) as part of a combination treatment for diffuse ...

A young university student had to force the doctors to do a CT scan, which diagnosed her Hodgkin lymphoma—a group of blood ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after ...

Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 5.22%, which has investors questioning if this is right time to buy.

Dave Coulier was diagnosed with cancer last year and immediately started chemotherapy, but his immune system left him so ...

CAR-T therapy costs about Rs 50 lakh in India including hospital fees, much less than the Rs 3-4 crore or more (before ...